- Iterum Therapeutics press release (NASDAQ:ITRM): Q2 GAAP EPS of -$0.30 beats by $0.15.
- Cash, cash equivalents and short-term investments were $11.7 million at June 30, 2024. Based on Iterum’s current operating plan, Iterum expects that its current cash, cash equivalents and short-term investments, including amounts raised in the 2024 Rights Offering, will be sufficient to fund its operations into 2025, including through the PDUFA date of October 25, 2024.
More on Iterum Therapeutics
#Iterum #Therapeutics #GAAP #EPS #beats #NASDAQITRM
